Abstract:BACKGROUND:The knowledge of Epidermal growth factor receptor (EGFR) expression in metastases of NSCLC was limited. In receptor-mediated targeted nuclide radiotherapy, tumor cells are killed with delivered radiation and therapeutic efficiency is mainly dependent on the receptor expression. Thus, the level and stability of receptor expression in both primary tumors and corresponding metastases is crucial in the assessment of a receptor as target. The goal of this study was to evaluate whether EGFR is suitable as target for clinical therapy.METHODS:Expression of EGFR was investigated immunohistochemically in paired samples of lymph node metastases and corresponding NSCLC primary lesions (n = 51). EGFR expression was scored as 0, 1+, 2+ or 3+.RESULTS:Positive (1+, 2+ or 3+) EGFR immunostaining was evident in 36 of 47 (76.6%) analysed NSCLC primary tumors, and in 78.7% of the corresponding lymph node metastases. When EGFR expression is classified as positive or negative, discordance between the primary tumors and the corresponding metastases was observed in 5 cases (10.6%). EGFR overexpression (2+ or 3+) was found in 53.2% (25/47) of the NSCLC primary tumors and 59.6% of the corresponding metastases. Nine out of the 47 paired samples (19.2%) were discordant: Only three patients who had EGFR overexpression in the primary tumors showed EGFR downregulation (0 or 1+) in lymph node metastases, while six patients changed the other way around.CONCLUSIONS:The EGFR expression in the primary tumor and the corresponding metastasis is discordant in about 10% of the patients. When overexpression is considered, the discordance is observed in about 20% of the cases. However, concerning EGFR overexpression in the primary tumors, similar expression in the metastases could be predicted with a reasonably high probability, which is encouraging for testing of EGFR targeted nuclide radiotherapy.

[Epidermal Growth Factor Receptor and Phosphorylated Akt Protein Expression in Non-Small-cell Lung Cancer].

[Phophorylated Akt Protein Expression in Non-Small Cell Lung Cancer].

Expression of P-EGFR and P-Akt Protein in Esophageal Squamous Cell Carcinoma and Its Prognosis

Expression of phospho-MAPK in non-small cell cancer and its clinicopathological significance

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Relationship between epidermal growth factor receptor and the prognosis of non-small cell lung cancer

Phosphorylated AKT1 is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer.

Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer

Expression and Clinical Significance of Vascular Endothelial Growth Factor and Epidermal Growth Factor in Non-Small Cell Lung Cancer

Detection of Phosphorylated AKT Expression and Cell Proliferation in Non-Small Cell Lung Cancer Tissue

Expression and Prognostic Value of AKT2 in Non-small Cell Lung Cancer

Expression of AEG-1-1 gene in NSCLC and its clinical significance

EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features

Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis

Epidermal growth factor receptor gene and protein abnormalities in non-small cell lung cancer

Positive Expression of P53, C-Erbb2 and MRP Proteins is Correlated with Survival Rates of NSCLC Patients.

[Expression and Clinical Significance of Ku70, Ku80 and DNA-PKcs Proteins in Patients with Stagei-Ii Non-Small Cell Lung Cancer by Tissue Microarray].

Expressions of cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer

Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors